CN117500518A - Il-2突变蛋白及包含其的药物 - Google Patents

Il-2突变蛋白及包含其的药物 Download PDF

Info

Publication number
CN117500518A
CN117500518A CN202180077914.6A CN202180077914A CN117500518A CN 117500518 A CN117500518 A CN 117500518A CN 202180077914 A CN202180077914 A CN 202180077914A CN 117500518 A CN117500518 A CN 117500518A
Authority
CN
China
Prior art keywords
leu
ala
glu
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180077914.6A
Other languages
English (en)
Chinese (zh)
Inventor
田中伸幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Local Independent Administrative Legal Entity Miyagi County Hospital Institution
Original Assignee
Local Independent Administrative Legal Entity Miyagi County Hospital Institution
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Local Independent Administrative Legal Entity Miyagi County Hospital Institution filed Critical Local Independent Administrative Legal Entity Miyagi County Hospital Institution
Publication of CN117500518A publication Critical patent/CN117500518A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180077914.6A 2020-09-18 2021-09-17 Il-2突变蛋白及包含其的药物 Pending CN117500518A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-157900 2020-09-18
JP2020157900 2020-09-18
PCT/JP2021/034438 WO2022059794A1 (ja) 2020-09-18 2021-09-17 Ｉｌ－２変異体タンパク質及びこれを含む医薬

Publications (1)

Publication Number Publication Date
CN117500518A true CN117500518A (zh) 2024-02-02

Family

ID=80776744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180077914.6A Pending CN117500518A (zh) 2020-09-18 2021-09-17 Il-2突变蛋白及包含其的药物

Country Status (5)

Country Link
US (1) US20240025956A1 (https=)
EP (1) EP4215542A4 (https=)
JP (1) JPWO2022059794A1 (https=)
CN (1) CN117500518A (https=)
WO (1) WO2022059794A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4285913A1 (en) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Highly effective adoptive t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59173773A (ja) 1983-03-24 1984-10-01 Fuji Electric Co Ltd 電車線の漏洩電流自動測定装置
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.

Also Published As

Publication number Publication date
JPWO2022059794A1 (https=) 2022-03-24
WO2022059794A1 (ja) 2022-03-24
US20240025956A1 (en) 2024-01-25
EP4215542A4 (en) 2024-11-20
EP4215542A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
US11236140B2 (en) Interleukin 15 fusion protein for tumor targeting therapy
Vincent et al. Tumor targeting of the IL‐15 superagonist RLI by an anti‐GD2 antibody strongly enhances its antitumor potency
US11866481B2 (en) TGF-β-receptor ectodomain fusion molecules and uses thereof
AU2007247380B2 (en) Antibody-targeted cytokines for therapy
EP4122951A1 (en) Interleukin-2 mutant and use thereof
JP2005507870A (ja) 低毒性のインターロイキン−２突然変異体
CN110267977A (zh) 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
US12552867B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
US20260035706A1 (en) Fusion polypeptides
KR20220008323A (ko) 면역 세포를 증식하는 il-2 돌연변이 단백질
CN117500518A (zh) Il-2突变蛋白及包含其的药物
CN116635403A (zh) pH依赖性突变型白细胞介素-2多肽
WO2024083226A1 (zh) 抗体融合蛋白及其制备和应用
US20070160575A1 (en) Anth1 chimeric antagonist
CN113603791A (zh) 一种融合蛋白及其应用
CN119371544A (zh) 一种单克隆抗体及其应用、核苷酸分子、载体或重组载体、以及转化体
WO2024037322A1 (zh) 一种IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
EP4549572A1 (en) Fusion protein
US20250049890A1 (en) Fusion proteins composed of an antibody and a mutein
KR20250135294A (ko) 암을 위한 il-15 작용제
HK40057771B (zh) 增殖免疫细胞的il-2突变体蛋白
HK40015886B (en) Albumin binding domain fusion proteins
HK40015886A (en) Albumin binding domain fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination